,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2012-05-07 07:01:00,Warner Chilcott' s ( WCRX ) first quarter 2012 earnings (excluding special items) of $1.16 per share handsomely beat the Zacks Consensus Estimate of 93 cents.,0.9501804113388062,0.026890965178608894,0.02292863465845585,positive,0.92328941822052
1,2012-05-07 07:01:00,Higher-than-expected revenues and lower-than-expected costs led to the earnings beat in the first quarter of 2012.,0.8903233408927917,0.07685180008411407,0.03282485902309418,positive,0.8134715557098389
2,2012-05-07 07:01:00,"Moreover, earnings beat the prior-year figure by 11.5%.",0.9534967541694641,0.02781178057193756,0.01869143731892109,positive,0.9256849884986877
3,2012-05-07 07:01:00,Revenues in the reported quarter declined 9.5% to $685 million.,0.017373833805322647,0.9736711382865906,0.008955036289989948,negative,-0.9562972784042358
4,2012-05-07 07:01:00,"The decline was primarily attributable to lower sales of its osteoporosis drug, Actonel -- acquired from Procter & Gamble Co. ( PG ) in 2009 -- due to generic competition.",0.018956167623400688,0.9658289551734924,0.015214857645332813,negative,-0.9468727707862854
5,2012-05-07 07:01:00,"Moreover, reduced sales of dermatological product Doryx also hurt revenues in the reported quarter.",0.017831280827522278,0.972633421421051,0.009535307064652443,negative,-0.9548021554946899
6,2012-05-07 07:01:00,"Revenues, however, beat the Zacks Consensus Estimate of $651 million.",0.9143929481506348,0.056886523962020874,0.028720494359731674,positive,0.8575063943862915
7,2012-05-07 07:01:00,Revenues from osteoporosis products declined 30.5% to $162 million.,0.017324112355709076,0.9731311202049255,0.009544769302010536,negative,-0.9558070302009583
8,2012-05-07 07:01:00,Actonel sales declined 37.1% to $146 million.,0.018151579424738884,0.9721223711967468,0.009726072661578655,negative,-0.9539707899093628
9,2012-05-07 07:01:00,The loss pf patent exclusivity of the drug in Western Europe in December 2010 hurt revenues in the quarter.,0.01795128546655178,0.972464919090271,0.009583747945725918,negative,-0.9545136094093323
10,2012-05-07 07:01:00,"Moreover, U.S. sales of the drug were down 47% in the first quarter of 2012 due to a 39% decrease in filled prescriptions.",0.016817482188344002,0.97291100025177,0.010271578095853329,negative,-0.9560934901237488
11,2012-05-07 07:01:00,"Warner Chilcott, which expects Actonel sales to continue declining, believes that osteoporosis therapy Atelvia (launched in December 2010) will help counter the loss of revenues from Actonel in the US.",0.24853423237800598,0.6944409608840942,0.05702482908964157,negative,-0.44590672850608826
12,2012-05-07 07:01:00,"Atelvia contributed $16 million to total revenues in the first quarter of 2012, up 23% sequentially.",0.9492163062095642,0.015140394680202007,0.03564321994781494,positive,0.9340758919715881
13,2012-05-07 07:01:00,Revenues from oral contraceptives climbed 3.6% to $142 million.,0.9512046575546265,0.020048018544912338,0.0287473164498806,positive,0.9311566352844238
14,2012-05-07 07:01:00,A 250% jump in the sales of Lo Loestrin FE (launched in the U.S. in 2011) to $28 million more than mitigated the 9% decline in the sales of Loestrin 24 FE.,0.9461541175842285,0.035852473229169846,0.017993487417697906,positive,0.9103016257286072
15,2012-05-07 07:01:00,Sales of Loestrin 24 FE declined primarily due to lower filled prescriptions.,0.01724047027528286,0.9693470001220703,0.01341248769313097,negative,-0.9521065354347229
16,2012-05-07 07:01:00,"Sales of hormone therapy products climbed 34.7% to $66 million in the first quarter of 2012, driven by increased sales of Estrace cream (up 49% to $52 million).",0.9555141925811768,0.020755013450980186,0.023730771616101265,positive,0.9347591996192932
17,2012-05-07 07:01:00,"Lower sales-related deductions, a 16% increase in filled prescriptions, in addition to higher average selling prices, led to the rise in Estrace cream sales in the reported quarter.",0.9365875124931335,0.03719309717416763,0.026219479739665985,positive,0.8993943929672241
18,2012-05-07 07:01:00,Sales of dermatological product Doryx declined 55% to $30 million.,0.016943905502557755,0.9731510877609253,0.009905095212161541,negative,-0.9562071561813354
19,2012-05-07 07:01:00,The decline was attributable to an increase in sales-related deductions coupled with a 4% decrease in filled prescriptions.,0.19982761144638062,0.7745480537414551,0.025624318048357964,negative,-0.5747204422950745
20,2012-05-07 07:01:00,We note that recently Warner Chilcott suffered a huge blow regarding the 150 mg dosage of Doryx.,0.02704045921564102,0.9553912281990051,0.017568286508321762,negative,-0.9283507466316223
21,2012-05-07 07:01:00,"On April 30, 2012, a U.S. district court issued a verdict regarding Mylan ( MYL ) and Impax Laboratories' ( IPXL ) applications to the FDA to sell their generic versions of the drug.",0.287718802690506,0.412949800491333,0.29933133721351624,negative,-0.12523099780082703
22,2012-05-07 07:01:00,The court ruled the generic versions of neither of the companies infringed the patent of Doryx.,0.06841858476400375,0.6654325127601624,0.2661488652229309,negative,-0.5970139503479004
23,2012-05-07 07:01:00,"Following the verdict, Mylan has entered the U.S. market with its generic version of Doryx 150 mg.",0.4916706681251526,0.008541855961084366,0.4997875392436981,neutral,0.4831288158893585
24,2012-05-07 07:01:00,"Sales of gastroenterology product, Asacol, climbed 13% to $211 million.",0.9547390937805176,0.02374238707125187,0.021518515422940254,positive,0.9309967160224915
25,2012-05-07 07:01:00,The increase was driven by higher sales in the U. S. aided by higher prices.,0.9487146735191345,0.02069084905087948,0.0305944737046957,positive,0.9280238151550293
26,2012-05-07 07:01:00,Sales of urology product Enablex declined 2% to $44 million.,0.016921987757086754,0.9728988409042358,0.010179185308516026,negative,-0.9559768438339233
27,2012-05-07 07:01:00,A 13% reduction in filled prescriptions hurt revenues during the quarter.,0.01869664527475834,0.9708306789398193,0.010472754016518593,negative,-0.9521340131759644
28,2012-05-07 07:01:00,"Selling, general and administrative (SG&A) expenses were down 22% in the reported quarter to $198 million.",0.01658247597515583,0.9725960493087769,0.010821498930454254,negative,-0.956013560295105
29,2012-05-07 07:01:00,The decline was primarily attributable to a reduction in expenses resulting from restructuring in Western Europe.,0.40498676896095276,0.5448552370071411,0.05015798658132553,negative,-0.13986846804618835
30,2012-05-07 07:01:00,Research and development (R&D) costs plummeted 19% to $25 million in the first quarter of 2012.,0.018938494846224785,0.9710908532142639,0.009970728307962418,negative,-0.9521523714065552
31,2012-05-07 07:01:00,"Apart from announcing financial results, Warner Chilcott announced that it will complete the restructuring of its operations in Western European nations such as Belgium, the Netherlands, France, Germany, Italy, Spain, Switzerland and the UK in 2012.",0.4628894329071045,0.01677677594125271,0.5203337669372559,neutral,0.44611266255378723
32,2012-05-07 07:01:00,The restructuring was announced in April 2011.,0.029587985947728157,0.0072223418392241,0.9631897211074829,neutral,0.022365644574165344
33,2012-05-07 07:01:00,Warner Chilcott undertook this move to counter the loss of revenues due to the loss of exclusivity of Actonel in Western Europe in late 2010.,0.46943607926368713,0.4470933675765991,0.08347056806087494,positive,0.022342711687088013
34,2012-05-07 07:01:00,Warner Chilcott incurred $50 million in restructuring costs in the first quarter of 2012.,0.0324925035238266,0.7562873959541321,0.21122011542320251,negative,-0.7237948775291443
35,2012-05-07 07:01:00,"As a result of the restructuring, the workforce at Warner Chilcott is expected to be trimmed by approximately 500 employees.",0.02479535900056362,0.9627311825752258,0.01247355155646801,negative,-0.9379358291625977
36,2012-05-07 07:01:00,"Following the adverse court ruling regarding Doryx 150 mg, Warner Chilcott trimmed its 2012 guidance.",0.03349806368350983,0.8773660063743591,0.08913589268922806,negative,-0.8438679575920105
37,2012-05-07 07:01:00,The company expects to earn in the range of $3.30-$3.40 per share (on an adjusted basis) on revenues between $2.4 billion and $2.5 billion.,0.18748821318149567,0.014734309166669846,0.7977774739265442,neutral,0.17275390028953552
38,2012-05-07 07:01:00,"Earlier, the company had said that it expected to end 2012 with adjusted earnings in the range of $3.60-$3.70 per share on revenues between $2.5 billion and $2.6 billion.",0.11143215000629425,0.012633854523301125,0.8759340047836304,neutral,0.09879829734563828
39,2012-05-07 07:01:00,The Zacks Consensus Estimate for 2012 currently hints at earnings of $3.64 per share on revenues of $2.53 billion.,0.10106837004423141,0.009753053076565266,0.8891786336898804,neutral,0.09131531417369843
40,2012-05-07 07:01:00,We currently have a Neutral recommendation on Warner Chilcott in the long run.,0.025588184595108032,0.13572457432746887,0.8386873006820679,neutral,-0.11013638973236084
41,2012-05-07 07:01:00,The stock carries a Zacks #3 Rank (Hold rating) in the short run.,0.2663762867450714,0.012906438671052456,0.7207172513008118,neutral,0.253469854593277
42,2012-05-07 07:01:00,To read this article on Zacks.com click here.,0.017961200326681137,0.01924508437514305,0.9627937078475952,neutral,-0.001283884048461914
43,2012-05-07 07:01:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
